Wellness products company Nature’s Sunshine (NASDAQ: NATR) fell short of the market’s revenue expectations in Q2 CY2026 as sales only rose 1.9% year on year to $117 million. The company’s full-year revenue guidance of $495 million at the midpoint came in 2.5% below analysts’ estimates. Its non-GAAP profit of $0.21 per share was 22.2% below analysts’ consensus estimates.
Is now the time to buy Nature's Sunshine? Find out by accessing our full research report, it’s free.
Nature's Sunshine (NATR) Q2 CY2026 Highlights:
- Revenue: $117 million vs analyst estimates of $123.7 million (1.9% year-on-year growth, 5.4% miss)
- Adjusted EPS: $0.21 vs analyst expectations of $0.27 (22.2% miss)
- Adjusted EBITDA: $11.33 million vs analyst estimates of $12.19 million (9.7% margin, 7.1% miss)
- The company dropped its revenue guidance for the full year to $495 million at the midpoint from $507.5 million, a 2.5% decrease
- EBITDA guidance for the full year is $50 million at the midpoint, below analyst estimates of $52.88 million
- Operating Margin: 4.7%, in line with the same quarter last year
- Free Cash Flow was -$1.94 million, down from $2.99 million in the same quarter last year
- Market Capitalization: $352.8 million
"We delivered a solid quarter, with constant currency sales growth of 4% across nearly all of our geographic regions," said Ken Romanzi, CEO of Nature's Sunshine.
Company Overview
Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ: NATR) manufactures and sells nutritional and personal care products.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years.
With $492 million in revenue over the past 12 months, Nature's Sunshine is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.
As you can see below, Nature's Sunshine’s sales grew at a tepid 4.4% compounded annual growth rate over the last three years. This shows it failed to generate demand in any major way and is a rough starting point for our analysis.
This quarter, Nature's Sunshine’s revenue grew by 1.9% year on year to $117 million, falling short of Wall Street’s estimates.
Looking ahead, sell-side analysts expect revenue to grow 5.4% over the next 12 months, similar to its three-year rate. This projection is above the sector average and suggests its newer products will fuel better top-line performance.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Cash Is King
Free cash flow isn’t a prominently featured metric in company financials and earnings releases, but we think it’s telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
Nature's Sunshine has shown mediocre cash profitability relative to peers over the last two years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 4.2%, below what we’d expect for a consumer staples business.
Taking a step back, we can see that Nature's Sunshine’s margin dropped by 1.2 percentage points over the last year. This along with its unexciting margin puts the company in a tough spot, and shareholders are likely hoping it can reverse course. If the trend continues, it could signal it’s becoming a more capital-intensive business.
Nature's Sunshine burned through $1.94 million of cash in Q2, equivalent to a negative 1.7% margin. The company’s cash flow turned negative after being positive in the same quarter last year, suggesting its historical struggles have dragged on.
Key Takeaways from Nature's Sunshine’s Q2 Results
It was good to see Nature's Sunshine narrowly top analysts’ gross margin expectations this quarter. On the other hand, its revenue missed and its EBITDA fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 14.3% to $17.48 immediately following the results.
Nature's Sunshine may have had a tough quarter, but does that actually create an opportunity to invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
